Conjupro Biotherapeutics, Inc.
Clinical trials sponsored by Conjupro Biotherapeutics, Inc., explained in plain language.
-
New drug CPO301 targets tough cancers in early trial
Disease control Recruiting nowThis early-phase trial tests CPO301, a drug that delivers a cancer-killing agent directly to tumor cells, in adults with advanced solid tumors (including lung cancer) that have not responded to other treatments. The main goals are to find a safe dose and check for early signs of …
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New antibody drug JMT108 enters human trials for advanced cancers
Disease control Recruiting nowThis early-phase study tests a new drug called JMT108 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive JMT108 by IV every t…
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New drug SYS6043 tested in patients with advanced cancers
Disease control Recruiting nowThis early-phase trial tests an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the …
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated May 20, 2026 11:53 UTC